3 High Growth Stocks With Healthy Balance Sheets Retail Investors May Be Missing

Oil price volatility is back in focus as markets weigh the risk of supply disruption around key shipping routes. That directly affects inflation expectations and interest rate paths, which can reshape how investors think about future earnings. In this backdrop, companies that analysts expect to grow earnings strongly while keeping balance sheets in good shape stand out. This article highlights three stocks from the Healthy high growth potential screener that fit that profile.

The stocks covered below are just a small sample, and the full screen surfaced 273 more companies that analysts expect to grow earnings strongly while keeping financial positions within defined thresholds. To identify which of those could suit your watchlist right now, head straight into the Healthy high growth potential screener.

Ardelyx (ARDX)

Overview: Ardelyx is a biopharmaceutical company that develops and sells medicines for patients with chronic kidney disease on dialysis and for those with irritable bowel syndrome with constipation, primarily through its IBSRELA and XPHOZAH therapies in the US and select international markets.

Operations: Ardelyx generates about US$451 million in revenue from the development and commercialization of its biopharmaceutical products.

Market Cap: US$997 million

Ardelyx may be of interest if you are looking for a focused healthcare company where product adoption and market access are central to the story. Analysts have published expectations for earnings and revenue growth as IBSRELA and XPHOZAH gain wider use, supported by partnerships and potential new indications. The stock is also described by some analysts as lowly valued relative to peers and future cash flow estimates. At the same time, it is important to weigh potential pressure points, including payer pushback on XPHOZAH, ongoing losses, reliance on a narrow product set and a higher cost of debt funding. If you want exposure to a specialist kidney and gastrointestinal player, Ardelyx is a company that may warrant a closer look as you consider how it fits your watchlist.

Ardelyx’s focused kidney and gastrointestinal story is tied to expectations for earnings to accelerate as IBSRELA and XPHOZAH build traction, yet pricing pressure and funding costs could change the picture fast, so it is worth reviewing the analyst forecasts for Ardelyx

Build your own high growth watchlist

Ardelyx and the other two stocks in this article all came from the same Simply Wall St screener, but the real value is in shaping filters around your own preferences. Use our flexible Screener to mix growth, valuation and balance sheet metrics, or start with one of our curated Investing Ideas for ready made shortlists.

Dutch Bros (BROS)

Overview: Dutch Bros is a US based drive thru coffee chain that operates and franchises shops serving coffee, energy drinks and related beverages, supported by branded products and accessories sold under the Dutch Bros and Blue Rebel labels.

Operations: Dutch Bros generates about US$1.74b from company operated shops and about US$141 million from franchising and other activities, almost entirely in the United States.

Market Cap: US$10.0b

Investors looking at Dutch Bros are weighing whether its rapid store rollout, loyalty app and higher margin specialty drinks can sustain growth at a pace that supports its current valuation. Revenue and earnings growth have recently outpaced the wider US Hospitality sector, and management has lifted 2026 revenue guidance while expanding into food and new sites through the Salad and Go acquisitions. At the same time, a high P/E, rising labor costs, insider selling and the risk of overbuilding stores indicate that expectations are demanding. For investors seeking exposure to a growing consumer brand focused on convenience and digital engagement, Dutch Bros may be a company to monitor closely.

Growth at Dutch Bros is tied to rapid store openings, app driven loyalty and higher margin drinks, yet the real story sits inside the analyst forecasts for Dutch Bros where expectations and risk quietly meet.

Unity Software (U)

Overview: Unity Software provides a software platform that lets developers and enterprises create, run, and grow real time 2D and 3D games and interactive experiences across mobile, PC, console, and extended reality devices, supported by AI tools for content creation, live operations, user acquisition, and monetization.

Operations: Unity Software generates about US$2.03b in revenue, primarily from its Computer Graphics segment, serving customers across the United States, Greater China, EMEA, the rest of the Asia Pacific, and other Americas.

Market Cap: US$18.9b

Unity Software is attracting attention from growth focused investors because its core game engine and AI driven advertising platform Vector sit at the center of real time 3D content and mobile monetization, while management is working toward GAAP profitability as soon as Q3 2026. Recent Q2 results showed revenue of US$546.47 million and a sharply smaller quarterly loss. Analysts have published forecasts that indicate expectations for faster earnings growth and a pivot to positive returns on equity over the next few years. The refocus on higher quality revenue through the exit of the ironSource ad network and the planned Unity 7 rollout point to a cleaner, more subscription heavy model. At the same time, heavy AI investment, high funding risk and tough competition mean this is not a low risk story.

Unity Software’s push toward GAAP profitability with a cleaner, subscription heavy model has many investors focused on the headline story. Yet the real inflection point may sit inside the analyst forecasts for Unity Software

Seeking Alternatives Before The Crowd Moves

Fresh ideas move fast. Some stocks are already building breakout momentum while others stay under the radar for now. Scan these focused shortlists before the window drops and act now.

• Spot companies with resilient earnings and sturdy balance sheets by running the list of solid balance sheet and fundamentals (48 results) while these financially grounded ideas are still being priced as if nothing has changed.
• Consider potential momentum in AI while it still feels early. Use the curated 56 AI infrastructure stocks to target enablers behind the hardware and data centers doing the heavy lifting.
• Explore commodity exposure with a tighter filter. The hand picked 29 elite gold producer stocks helps you focus on producers with scale while many investors remain on the sidelines.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com